External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ASH 2020
Roche and Genentech at

ASH 2020

December 05 - December 08
San Diego, USA
hematology.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
09:30 AM
Duration 10mins Virtual
Effect of Moderate and Severe Hemophilia A on Daily Life in Children and Their Caregivers: A CHESS Paediatrics Study Analysis
Khair K, Nissen F, Silkey M, Burke T, Shang A, Aizenas M, Meier O, O’Hara J, Noone D
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 10mins Virtual
Five-Year Analysis of MURANO Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy
Kater AP, Kipps TJ, Eichhorst BF, Hillmen P, D'Rozario J, Owen C, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Wilson C, Wu J, Jiang Y, Lefebure M, Boyer M, Seymour JF
Haematology | Chronic Lymphocytic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:30 AM
Duration 10mins Virtual
Clonal dynamics after venetoclax-obinutuzumab therapy: Novel insights from the randomized, phase 3 CLL14 trial
Al-Sawaf O, Zhang C, Robrecht S, Wilson C, Tandon M, Ching T, Fink A-M, Tausch E, Ritgen M, Kreuzer K-A, Schary W, Wendtner C-M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K
Haematology - Oncology | Chronic Lymphocytic Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:30 PM
Duration 10mins Virtual
Initial Clinical Activity and Safety of Cevostamab (BFCR4350A), a FcRH5xCD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Cohen AD, Harrison S, Krishnan A, Fonseca R, Forsberg PA, Spencer A, Berdeja JG, Laubach JP, Li M, Choeurng V, Vaze A, Samenini D, Sumiyoshi T, Cooper J, Fine BM, Trudel S
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:15 PM
Duration 10mins Virtual
Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib (Cobi) as a Single Agent and in Combination with Venetoclax (Ven) with or without Atezolizumab (Atezo) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Schjesvold F, Ribrag V, Rodriguez-Otero P, Robak PJ, Hansson M, Hajek R, Alegre Amor A, Martinez-Lopez J, Onishi M, Gallo JD, Raval A, Deshpande S, Malhi V, Hong W-J, Raab MS
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:15 PM
Duration 10mins Virtual
Single-agent Mosunetuzumab is a Promising, Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B‑cell Lymphoma
Olszewski A, Avigdor A, Babu S, Levi I, Abadi U, Holmes H, McKinney M, Horowitz N, McCord R, Xie Y, Chen C, Sarouei K, Qayum N, O'Hear C, Sellam G, Eradat H
Haematology - Oncology | Diffuse Large B-Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:45 PM
Duration 10mins Virtual
Glofitamab Step-Up Dosing Induces High Response Rates in Patients with Hard-to-treat Refractory or Relapsed (R/R) Non-Hodgkin Lymphoma (NHL)
Hutchings M, Carlo-Stella C, Bachy E, Offner FC, Morschhauser F, Crump M, Iacoboni G, Sureda A, Martinez-Lopez J, Lundberg L, Dixon M, Perez Callejo D, Relf J, Carlile D, Piccione E, Humphrey K, Dickinson MJ
Haematology - Oncology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 10mins Virtual
Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
Mascarenhas J, Anders A, Burbury K, El-Galaly T, Gerds A, Gupta V, Higgins B, Kovic B, Maffioli M, Mesa R, Palmer J, Passamonti F, Rambaldi A, Ross D, Vannucchi A, Yacoub A
Haematology | Polycythemia Vera

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:30 AM
Duration 10mins Virtual
Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients by Measuring Circulating Tumor DNA
Herrera AF, Tracy S, Croft B, Opat S, Ray J, Musick L, Paulson J, Sehn LH, Jiang Y
Haematology - Oncology | Diffuse Large B-Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:30 AM
Duration 10mins Virtual
Polatuzumab Vedotin plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
Gritti G, Marlton P, Phillips T, Arthur C, Bannerji R, Corradini P, Johnston A, Seymour JF, Yuen S, Hirata J, Musick L, Saha S, Croft B, Flowers C
Haematology | Diffuse Large B-Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 10mins Virtual
Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
Assouline S, Kim WS, Sehn LH, Schuster SJ, Cheah CY, Nastoupl LJ, Shadman M, Yoon SS, Matasar MJ, Diefenbach C, Gregory GP, Bartlett NL, Wei MC, Doral MY, Yin S, Negricea R, Li C-C, Penuel E, Huang H, Budde LE
Haematology - Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.